Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2024 Feb 28;29(5):1038.
doi: 10.3390/molecules29051038.

Isolation, Purification, Fractionation, and Hepatoprotective Activity of Polygonatum Polysaccharides

Affiliations

Isolation, Purification, Fractionation, and Hepatoprotective Activity of Polygonatum Polysaccharides

Yutong Wang et al. Molecules. .

Abstract

In this study, three homogeneous fractions, PSP-N-b-1, PSP-N-b-2, and PSP-N-c-1, were obtained from an aqueous extract of Polygonatum using DEAE cellulose column chromatography, CL-6B agarose gel chromatography, and Sephadex G100 chromatography. Their monosaccharide compositions and molecular weights were analyzed. The results revealed that PSP-N-b-1, PSP-N-b-2, and PSP-N-c-1 are primarily composed of six monosaccharides: Man (mannose), GlcA (glucuronic acid), Rha (rhamnose), GalA (galacturonic acid), Glc (glucose), and Ara (arabinose), with molecular weights of 6.3 KDa, 5.78 KDa, and 3.45 KDa, respectively. Furthermore, we observed that Polygonatum polysaccharides exhibited protective effects against CCL4-induced liver damage in HepG2 cells in vitro, operating through both anti-oxidant and anti-inflammatory mechanisms. Our research findings suggest that Polygonatum polysaccharides may emerge as a promising option in the development of hepatoprotective drugs or functional foods with anti-inflammatory and antioxidant properties.

Keywords: Polygonatum polysaccharides; anti-inflammatory; anti-oxidant; hepatoprotective activity.

PubMed Disclaimer

Conflict of interest statement

The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.

Figures

Figure 1
Figure 1
Elution curve of PSPs from DEAE-cellulose column (A), elution curve of PSP-N on Sepharose CL-6B gel (B), elution curve of PSP-N-b on Sephadex G100 gel (C), elution curve of PSP-N-c on Sephadex G100 gel (D).
Figure 2
Figure 2
Monosaccharide composition and molecular weight determination results of each component of PSP-N. Monosaccharide composition: PSP-N-b-1 (A), PSP-N-b-2 (B), and PSP-N-c-1 (C); Molecular weights: PSP-N-b-1 (D), PSP-N-b-2 (E), and PSP-N-c-1 (F).
Figure 3
Figure 3
Effect of Polygonatum polysaccharides on the morphology of HepG2 cells induced by CCL4. Normal control group (A), model group (B), low-, medium-, and high-dose groups of PSP-N-b-1 (CE), low-, medium-, and high-dose groups of PSP-N-b-2 (FH), low-, medium-, and high-dose groups of PSP-N-c-1 (IK).
Figure 4
Figure 4
Effect of Polygonatum polysaccharides on ALT and AST of HepG2 induced by CCL4: AST (A), ALT (B). Compared with Con group, ## p < 0.01; compared with Mod group, ** p < 0.01.
Figure 5
Figure 5
Effects of PSPs on oxidative indices and inflammatory cytokines in CCl4-induced HepG2 cells. MDA (A), SOD (B), CAT (C), TNF-α (D), IL-1β (E), and IL-6 (F). Compared with Con group, ## p < 0.01; compared with Mod group, * p < 0.05, ** p < 0.01.

Similar articles

Cited by

References

    1. Xu G., Yuan G., Lu X., An L., Sheng Y., Du P. Study on the effect of regulation of Cordyceps militaris polypeptide on the immune function of mice based on a transcription factor regulatory network. Food Funct. 2020;11:6066–6077. doi: 10.1039/D0FO01043J. - DOI - PubMed
    1. Keles U., Ow J., Kuentzel K., Zhao L., Kaldis P. Liver-derived metabolites as signaling molecules in fatty liver disease. Cell. Mol. Life Sci. CMLS. 2022;80:4. doi: 10.1007/s00018-022-04658-8. - DOI - PMC - PubMed
    1. Khan M., Lee C., Kim S. Non-alcoholic fatty liver disease and liver secretome. Arch. Pharmacal Res. 2022;45:938–963. doi: 10.1007/s12272-022-01419-w. - DOI - PMC - PubMed
    1. Stravitz R., Lee W. Acute liver failure. Lancet. 2019;394:869–881. doi: 10.1016/S0140-6736(19)31894-X. - DOI - PMC - PubMed
    1. Loomba R., Friedman S., Shulman G. Mechanisms and disease consequences of nonalcoholic fatty liver disease. Cell. 2021;184:2537–2564. doi: 10.1016/j.cell.2021.04.015. - DOI - PubMed

LinkOut - more resources